Substitution of a hydrogen atom with its heavy isotope deuterium entails the addition of one
neutron to a molecule. Despite being a subtle change, this structural modification, known as …

In the present work, we report compilation and analysis of 245 drugs, including small and
macromolecules approved by the US FDA from 2015 until June 2020. Nearly 29% of the …

Background Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, inhibits
cytokine signaling in psoriasis pathogenesis. Objective The objective of this study was to …

Psoriasis is a chronic inflammatory disease characterised by sharply demarcated
erythematous and scaly skin lesions accompanied by systemic manifestations. Classified by …

Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes
four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling …

The Janus tyrosine kinase (JAK) family of non-receptor tyrosine kinases includes four
isoforms (JAK1, JAK2, JAK3, and TYK2) and is responsible for signal transduction …

Protein kinases play a major role in cellular activation processes, including signal
transduction by diverse immunoreceptors. Given their roles in cell growth and death and in …

All along the drug development process, one of the most frequent adverse side effects,
leading to the failure of drugs, is the cardiac arrhythmias. Such failure is mostly related to the …

Psoriasis is a heterogeneous, inflammatory, autoimmune skin disease that affects up to 2%
of the world's population. There are many treatment modalities including topical medicines …

Psoriasis is an immune-mediated disease, with the interleukin (IL)-23/IL-17 axis currently
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …